Ustekinumab Versus Anti-tumour Necrosis Factor Alpha Agents as Second-Line Biologics in Crohn's Disease
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource, 1 online resource.
- Sprache
-
Englisch
- Erschienen in
-
Ustekinumab Versus Anti-tumour Necrosis Factor Alpha Agents as Second-Line Biologics in Crohn's Disease ; volume:68 ; number:7 ; day:17 ; month:3 ; year:2023 ; pages:3119-3128 ; date:7.2023
Digestive diseases and sciences ; 68, Heft 7 (17.3.2023), 3119-3128, 7.2023
- Urheber
-
Eriksson, Carl
Söderling, Jonas
Karlqvist, Sara
Bröms, Gabriella
Everhov, Åsa H.
Bergemalm, Daniel
Ludvigsson, Jonas F.
Olén, Ola
Halfvarson, Jonas
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s10620-023-07897-2
- URN
-
urn:nbn:de:101:1-2023092711121255214559
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:50 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Eriksson, Carl
- Söderling, Jonas
- Karlqvist, Sara
- Bröms, Gabriella
- Everhov, Åsa H.
- Bergemalm, Daniel
- Ludvigsson, Jonas F.
- Olén, Ola
- Halfvarson, Jonas
- SpringerLink (Online service)
Ähnliche Objekte (12)
The severity of ankylosing spondylitis and responses to anti-tumour necrosis factor biologics are not influenced by the tumour necrosis factor receptor polymorphism incriminated in multiple sclerosis
Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register
Ustekinumab (Stelara) : Ustekinumab bei besonderen CED-Situationen
Comparative effectiveness of second-line biological therapies for ulcerative colitis and Crohn’s disease in patients with prior failure of anti-tumour necrosis factor treatment
Small tumor necrosis factor receptor biologics inhibit the tumor necrosis factor-p38 signalling axis and inflammation
Risk of Treatment Discontinuation among Patients with Psoriasis Initiated on Ustekinumab and Other Biologics in the USA
AVT04: An Ustekinumab Biosimilar
Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey
A longitudinal single-cell atlas of anti-tumour necrosis factor treatment in inflammatory bowel disease
Biologics in therapy
Correction to: AVT04: An Ustekinumab Biosimilar
Correction to: AVT04: An Ustekinumab Biosimilar
The severity of ankylosing spondylitis and responses to anti-tumour necrosis factor biologics are not influenced by the tumour necrosis factor receptor polymorphism incriminated in multiple sclerosis
Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register
Ustekinumab (Stelara) : Ustekinumab bei besonderen CED-Situationen
Comparative effectiveness of second-line biological therapies for ulcerative colitis and Crohn’s disease in patients with prior failure of anti-tumour necrosis factor treatment
Small tumor necrosis factor receptor biologics inhibit the tumor necrosis factor-p38 signalling axis and inflammation
Risk of Treatment Discontinuation among Patients with Psoriasis Initiated on Ustekinumab and Other Biologics in the USA
AVT04: An Ustekinumab Biosimilar
Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey
A longitudinal single-cell atlas of anti-tumour necrosis factor treatment in inflammatory bowel disease
Biologics in therapy
Correction to: AVT04: An Ustekinumab Biosimilar
Correction to: AVT04: An Ustekinumab Biosimilar
The severity of ankylosing spondylitis and responses to anti-tumour necrosis factor biologics are not influenced by the tumour necrosis factor receptor polymorphism incriminated in multiple sclerosis
Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register
Ustekinumab (Stelara) : Ustekinumab bei besonderen CED-Situationen
Comparative effectiveness of second-line biological therapies for ulcerative colitis and Crohn’s disease in patients with prior failure of anti-tumour necrosis factor treatment
Small tumor necrosis factor receptor biologics inhibit the tumor necrosis factor-p38 signalling axis and inflammation
Risk of Treatment Discontinuation among Patients with Psoriasis Initiated on Ustekinumab and Other Biologics in the USA
AVT04: An Ustekinumab Biosimilar
Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey
A longitudinal single-cell atlas of anti-tumour necrosis factor treatment in inflammatory bowel disease
Biologics in therapy
Correction to: AVT04: An Ustekinumab Biosimilar